MARKET

BRTX

BRTX

Biorestorative Therapies Inc
NASDAQ
0.2721
+0.0074
+2.80%
Pre Market: 0.2750 +0.0029 +1.07% 06:12 04/01 EDT
OPEN
0.2690
PREV CLOSE
0.2647
HIGH
0.2776
LOW
0.2600
VOLUME
8.32K
TURNOVER
--
52 WEEK HIGH
2.045
52 WEEK LOW
0.1900
MARKET CAP
6.93M
P/E (TTM)
-0.1718
1D
5D
1M
3M
1Y
5Y
1D
BioRestorative Therapies reports blinded data from mesenchymal stem cells trial
TipRanks · 1d ago
BioRestorative Announces Blinded Data From Phase 2 Clinical Trial Evaluating Hypoxic-Cultured Mesenchymal Stem Cells For Treatment Of Chronic Lumbar Disc Disease; Data Shows 50% Or More Of Patients Reporting >50% Improvement In Key Pain And Function Scales
Benzinga · 1d ago
BioRestorative reports positive blinded Phase 2 data for BRTX-100 in lumbar disc disease
Reuters · 1d ago
BIORESTORATIVE THERAPIES INC - NO ADVERSE EVENTS RELATED TO DOSE-LIMITING TOXICITIES ASSOCIATED WITH HYPOXIC-CULTURED MESENCHYMAL STEM CELLS
Reuters · 1d ago
Weekly Report: what happened at BRTX last week (0323-0327)?
Weekly Report · 2d ago
BioRestorative Therapies Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $19.600K Miss $520.000K Estimate
Benzinga · 5d ago
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/24 21:25
Weekly Report: what happened at BRTX last week (0316-0320)?
Weekly Report · 03/23 09:18
More
About BRTX
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.

Webull offers BioRestorative Therapies Inc stock information, including NASDAQ: BRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRTX stock methods without spending real money on the virtual paper trading platform.